Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion

被引:2
作者
Fukuoka, N [1 ]
Morita, S
Hamatani, S
Okada, H
Kondoh, M
Imai, T
Ohnishi, S
Itoh, S
机构
[1] Kagawa Med Univ, Dept Hosp Pharm, Kagawa, Japan
[2] Kagawa Med Univ, Dept Pediat, Kagawa, Japan
来源
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 2002年 / 122卷 / 08期
关键词
Wilson's disease; D-penicillamine; urinary copper excretion; administration schedule;
D O I
10.1248/yakushi.122.585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to increase the amount of copper excreted resulting from the administration of D-penicillamine (DP) in pediatric Wilson's disease (WD) patients. By measuring the urinary copper excretion after adjusting the administration schedules, the appropriate timing for DP administration was investigated. The subjects were three brothers with pediatric WD. The initial daily dose of DP was 5 mg/kg/day, and gradually increased to the maintenance dose of 20 mg/kg/day. Until the maintenance daily dose was reached, DP was administered 2 h after the morning and evening meal. After reaching the maintenance daily dose of DP, the appropriate timing for taking DP was investigated in both the morning and evening. Three schedules of DP administration were compared: 2 h after meals; 30 min before meals (with fasting); and 1 h before the morning and 1.5 before the evening meal (direction 1). The resulting urinary copper excretion on each dosing schedule was compared. Little difference was found in urinary copper excretion on the first two schedules, i.e., 2 h after meals and 30 min before meals. When DP was administered 30 min before meals, urinary copper excretion [mug/day] was 1173 in the first brother, 918 in the second, and 875 in the third. When DP was administered according to direction 1, however, urinary copper excretion was increased significantly to 1701 in the first brother, 2701 in the second, and 3808 in the third. It is known that the efficiency of urinary copper excretion with DP administration depends on the maintenance of chelating ability after absorption from the gastrointestinal tract. Our results indicate that the excretion was lower when DP was administered 2 h after or 30 min before meals (with fasting), as recommended in the package insert. Thus to achieve better copper excretion efficiency, direction 1 is recommended for WD patients.
引用
收藏
页码:585 / 588
页数:4
相关论文
共 36 条
  • [21] Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease
    Berger, Benjamin
    Mader, Irina
    Damjanovic, Kornelija
    Niesen, Wolf-Dirk
    Stich, Oliver
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 127 : 122 - 124
  • [22] Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients
    Katerji, Meghri
    Barada, Kassem
    Jomaa, Mustapha
    Kobeissy, Firas
    Makkawi, Ahmad-Kareem
    Abou-Kheir, Wassim
    Usta, Julnar
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2017, 10
  • [23] Concurrent administration of D-penicillamine and zinc has no advantages over the use of either single agent on copper excretion in the rat
    Domingo, JL
    Gómez, M
    Jones, MM
    TOXICOLOGY, 1998, 126 (03) : 195 - 201
  • [24] D-penicillamine reduces serum oxidative stress in Alzheimer's disease patients
    Squitti, R
    Rossini, PM
    Cassetta, E
    Moffa, F
    Pasqualetti, P
    Cortesi, M
    Colloca, A
    Rossi, L
    Finazzi-Agro, A
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 (01) : 51 - 59
  • [25] Treatment with D-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease
    Gromadzka, Grazyna
    Karpinska, Agata
    Przybylkowski, Adam
    Litwin, Tomasz
    Wierzchowska-Ciok, Agata
    Dziezyc, Karolina
    Chabik, Grzegorz
    Czlonkowska, Anna
    BIOMETALS, 2014, 27 (01) : 207 - 215
  • [26] Spatial investigation of the elemental distribution in Wilson's disease liver after D-penicillamine treatment by LA-ICP-MS
    Hachmoeller, Oliver
    Zibert, Andree
    Zischka, Hans
    Sperling, Michael
    Groba, Sara Reinartz
    Gruenewald, Inga
    Wardelmann, Eva
    Schmidt, Hartmut H. -J.
    Karst, Uwe
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2017, 44 : 26 - 31
  • [27] Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson's disease with D-penicillamine treatment failure
    Chen, Dingbang
    Zhou, Xiangxue
    Hou, Haiman
    Feng, Li
    Liu, JunXiu
    Liang, Yinyin
    Lin, Xiaopu
    Zhang, Jiwei
    Wu, Chao
    Liang, Xiuling
    Pei, Zhong
    Li, Xunhua
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (04) : 310 - 316
  • [28] Copper and Zinc in the Serum, Urine, and Hair of Patients with Wilson's Disease Treated with Penicillamine and Zinc
    Dastych, Milan
    Prochazkova, Dagmar
    Pokorny, Antonin
    Zdrazil, Libor
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2010, 133 (03) : 265 - 269
  • [29] Copper and Zinc in the Serum, Urine, and Hair of Patients with Wilson’s Disease Treated with Penicillamine and Zinc
    Milan Dastych
    Dagmar Procházková
    Antonin Pokorný
    Libor Zdražil
    Biological Trace Element Research, 2010, 133 : 265 - 269
  • [30] D-Penicillamine improved laparoscopic and histological findings of the liver in a patient with Wilson's disease: 3-year follow-up after diagnosis of Coombs-negative hemolytic anemia of Wilson's disease
    Sakaida, I
    Kawaguchi, K
    Kimura, T
    Tamura, F
    Okita, K
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (06) : 646 - 651